Jeffrey R. Jackson

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang et al. · Cancer Immunology Immunotherapy · 2011 · 777 citations · Full text

Medicine, Immunology, Oncology +10

The codependence of angiogenesis and chronic inflammation

Jeffrey R. Jackson, Michael Seed, Charles H. Kircher et al. · The FASEB Journal · 1997 · 699 citations

Veterinary Medicine, Immunology, Cell Signaling +14

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 372 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 254 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jeffrey R. Jackson, Aidan G. Gilmartin, Christina S. Imburgia et al. · PubMed · 2000 · 233 citations

Life Sciences, Cell Biology, Molecular Biology +17